Letter to the Editor

JCP
Vitamin B12 Deficiency Risk With Metformin for Weight Management in Second-Generation Antipsychotic Recipients: Reply to Mulsant et al
Letter to the Editor

March 18, 2026

Daggolu and Chen reply to a letter commenting on their study of metformin use in patients receiving second-generation antipsychotics.
,
JCP
Concurrent Metformin and Second-Generation Antipsychotics: The Need to Add Vitamin B12
Letter to the Editor

March 18, 2026

The authors recommend vigilance for potential B12 deficiency when coprescribing metformin and antipsychotics.
, ,
JCP
Neural Dysconnectivity and Affective Disorders: Integrating Sleep and Emotional Regulation Perspectives
Letter to the Editor

March 16, 2026

The authors discuss sleep disturbance in the context of recent research on functional dysconnectivity in the brain’s triple networks.
, , , et al
JCP
Triple Network Dysconnectivity and Sleep Disturbance in Young People With Suicidal Ideation: Reply to Ferruzzi et al
Letter to the Editor

March 16, 2026

Cheng et al reply to a letter regarding their recent study of triple network functional dysconnectivity in major affective disorders.
, ,
PCC
Psychosis and Kratom
Letter to the Editor

March 10, 2026

The authors discuss the possible association between psychosis and kratom use.
,
PCC
CTRA, Stress, and Yoga
Letter to the Editor

February 24, 2026

The authors examine the historical context of stress, the neurobiological mechanisms of conserved transcriptional response to adversity and stress, and how yoga practices counteract its effects.
,
PCC
Psychotropic-Related Aspiration Hazards
Letter to the Editor

February 10, 2026

The authors discuss the importance of a choking prevention policy to identify those at heightened risk for choking hazards, particularly psychiatric patients.
,
PCC
Lysing Catatonia to Uncover the Driving Illness
Letter to the Editor

January 29, 2026

The author comments on a recent PCC article and offers an alternative diagnostic perspective.
PCC
Clarifying the Delirium in Bell’s Mania: Reply to Intrator
Letter to the Editor

January 29, 2026

The authors respond to a letter to the editor commenting on their article.
, , , et al
JCP
Rationale for Clozapine Trial
Letter to the Editor

January 28, 2026

Dr Mattes comments on a recent article examining the use of clozapine versus other antipsychotic options.
JCP
The Position of Clozapine in Patients with Treatment-Resistant Schizophrenia: Reply to Mattes
Letter to the Editor

January 28, 2026

Dr Andrade replies to a letter about his article on factors affecting choice of clozapine versus other antipsychotics.
JCP
Urological Commentary on Ketamine-Associated Uropathy
Letter to the Editor

January 26, 2026

The author comments on a recent article reviewing ketamine-associated uropathy in therapeutic and nontherapeutic settings.
JCP
Ketamine-Associated Uropathy in Therapeutic Contexts: Reply to Abdelrahman
Letter to the Editor

January 26, 2026

Dr Andrade responds to a letter commenting on his recent review of ketamine-associated uropathy in therapeutic and nontherapeutic settings.
PCC
Kratom-Induced Psychosis
Letter to the Editor

January 8, 2026

The author comments on the complexity of substance-induced presentations, particularly those related to newly available psychoactive substances such as kratom.
PCC
Semaglutide for Alcohol Use Disorder
Letter to the Editor

January 1, 2026

The authors explore potential mechanisms underlying the relationship between GLP-1 agonists and AUD as well as studies evaluating semaglutide for AUD.
,
JCP
Reframing the Discussion on Finasteride and Neuropsychiatric Safety
Letter to the Editor

December 17, 2025

The authors comment on a recent article by Brezis, who argues that finasteride is causally linked to depression, suicidality, and other neuropsychiatric reactions.
,
JCP
Finasteride-Induced Neuropsychiatric Reactions: No Room for Complacency
Letter to the Editor

December 17, 2025

Dr Brezis replies to a letter by Tringali and Tringali regarding his recent article.
PCC
Psychosis Screening in Genetic Disorders
Letter to the Editor

December 4, 2025

The author discusses routine monitoring for the development of psychotic symptoms among individuals with rare genetic disorders that confer risk for psychosis.
PCC
Culturally Adaptive Mental Health Care
Letter to the Editor

December 2, 2025

The author discusses the culturally adaptive work of Dr Vidya Sagar, whose mid-20th-century innovations in family-centered care laid the groundwork for India’s unique trajectory in community psychiatry.
JCP
Burnout in Psychiatric Doctors Before and After COVID-19: A Critical Commentary
Letter to the Editor

December 1, 2025

The authors comment on a recent meta-analysis by Johnson and colleagues.
,
JCP
Exposure Therapy for Perinatal OCD: Navigating Evidence and Discomfort
Letter to the Editor

November 17, 2025

Although patients and providers must be prepared for the temporary distress associated with exposure and response prevention, it remains the most effective nonpharmacologic treatment for OCD.
, ,
JCP
From Today’s Observations to Tomorrow’s Standards in Women’s Psychiatry
Letter to the Editor

November 3, 2025

The authors comment on a recent study of treatment use and preference in women with mood disorders.
, ,
JCP
Context Matters in Treatment Preference of Women With Mood Disorders: Reply to Świeczkowski et al
Letter to the Editor

November 3, 2025

The authors reply to Świeczkowski and colleagues’ letter regarding their recent study
,
JCP
Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine
Letter to the Editor

October 29, 2025

The authors comment on a recent chart review by Meisner et al.
,

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe